COST-EFFECTIVENESS OF LANADELUMAB AND C1-INHIBITORS FOR PROPHYLAXIS AGAINST ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA

被引：0
|
作者：
Lubinga, S. J. [1 ]
Agboola, F. O. [2 ]
Lin, G. [3 ]
Seidner, M. [2 ]
Rind, D. [2 ]
Carlson, J. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Inst Clin & Econ Review, Boston, MA USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1657
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO24
引用
收藏
页码：S339 / S339
页数：1
相关论文
共 50 条
  • [1] Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks
    Bernstein, Jonathan A.
    Tyson, Christopher
    Relan, Anurag
    Adams, Philippe
    Magar, Raf
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 203 - +
  • [2] The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks A Summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum
    Agboola, Foluso
    Lubinga, Solomon
    Carlson, Josh
    Lin, Grace A.
    Dreitlein, William B.
    Pearson, Steven D.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (02): : 143 - 148
  • [3] Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks
    Tyson, Christopher
    Relan, Anurag
    Adams, Philippe
    Haynes, Angela
    Magar, Raf
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (05) : 359 - 359
  • [4] Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
    Johnston, Douglas T.
    Busse, Paula J.
    Riedl, Marc A.
    Maurer, Marcus
    Anderson, John
    Nurse, Christina
    Inhaber, Neil
    Yu, Ming
    Banerji, Aleena
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (10): : 1391 - 1395
  • [5] Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation
    Bouillet, Laurence
    Bocquet, Alexis
    Belbezier, Aude
    Boccon-Gibod, Isabelle
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (03) : 391 - +
  • [6] Real-world effectiveness and safety of lanadelumab for prophylaxis of hereditary angioedema attacks: 2-year interim results from the enable study
    Saguer, I. Martinez
    Cancian, M.
    Kinaciyan, T.
    Kessel, A.
    Andriotti, T.
    Botha, J.
    Wuillemin, W.
    [J]. ALLERGY, 2023, 78 : 27 - 28
  • [7] A COST-EFFECTIVENESS COMPARISON OF ICATIBANT AND C1-ESTERASE INHIBITOR CONCENTRATE FOR THE SYMPTOMATIC TREATMENT OF ACUTE ATTACKS OF TYPES I AND II HEREDITARY ANGIOEDEMA IN THE UK SETTING
    Helbert, M.
    Pang, F.
    Alvarez-Reyes, M.
    Pearson, I
    Wolowacz, S.
    Diwakar, L.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A513 - A513
  • [8] Recombinant C1 inhibitor for Acute Attacks of Hereditary Angioedema
    Reshef, A.
    Leibovich, I
    [J]. ALLERGY, 2009, 64 : 571 - 571
  • [9] The goal of prophylaxis against hereditary angioedema attacks is no attacks: a summary of findings for approved and investigational products
    Aygoeren-Puersuen, E.
    Farkas, H.
    Moldovan, D.
    Martinez-Saguer, I
    Hao, J.
    Lu, P.
    Schranz, J.
    [J]. ALLERGY, 2017, 72 : 596 - 596
  • [10] TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA WITH C1-INHIBITOR CONCENTRATE
    AGOSTONI, A
    BERGAMASCHINI, L
    MARTIGNONI, G
    CICARDI, M
    MARASINI, B
    [J]. ANNALS OF ALLERGY, 1980, 44 (05): : 299 - 301
12345